Advances in CAR T-Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice

Advances in CAR T-Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice

Friday, December 10, 2021
Webinar -- 11:30 AM ET
https://www.clinicaloptions.com/CARTAtlanta2021Join1

Agenda

CAR T-Cell Therapy for Lymphomas

CAR T-Cell Therapy for Myeloma

CAR T-Cell Therapies for ALL

Identifying and Managing CAR T-Cell–Mediated Toxicities

Faculty

Program Director
Michael R. Bishop, MD

Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois

Faculty
Jesús G. Berdeja, MD

Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Faculty
Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Target Audience
This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate into practice up-to-date efficacy and safety data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Discuss considerations associated with CAR T-cell therapy, including patient selection, referring patients to specialized centers, and the importance of collecting patient-reported outcomes
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.